Sizemore Gina, Rudisill Toni Marie
West Virginia University.
J Appalach Health. 2021;3(3):97-109. doi: 10.13023/jah.0303.08.
Triple negative breast cancer is an aggressive breast cancer with decreased five-year survival, increased risk for recurrence, and higher risk for metastases. Unlike other breast cancers, it has no targeted treatment and has heterogeneous genetics which make classification and treatment difficult.
The purpose of our research was to compare triple negative breast cancer to non-triple negative breast cancer to identify key epidemiologic factors that might lead to improved basic science directives for biomarkers, treatments, and classification.
The state cancer registry was used to provide the first West Virginia state-wide population evaluation of triple negative breast cancer.
The research reveals novel results that tumor grade increases exponentially with the age at diagnosis.
This creates an epidemiologic foundation for future research to define whether the disease, access to care, biology of aging, or some other factor cause this significant finding. In addition, results reveal decreased use of testing that could be increased to improve biomarker identification, targeted treatments, and classification of triple negative breast cancer.
三阴性乳腺癌是一种侵袭性乳腺癌，五年生存率降低，复发风险增加，转移风险更高。与其他乳腺癌不同，它没有靶向治疗方法，并且具有异质性遗传学特征，这使得分类和治疗都很困难。
我们研究的目的是比较三阴性乳腺癌和非三阴性乳腺癌，以确定可能有助于改进生物标志物、治疗方法和分类的基础科学指导方针的关键流行病学因素。
利用州癌症登记处对西弗吉尼亚州全州范围内的三阴性乳腺癌进行首次人群评估。
研究揭示了新的结果，即肿瘤分级随诊断年龄呈指数增长。
这为未来的研究奠定了流行病学基础，以确定是疾病本身、获得医疗服务的机会、衰老生物学还是其他因素导致了这一显著发现。此外，结果显示可能增加用于改善三阴性乳腺癌生物标志物识别、靶向治疗和分类的检测方法的使用。
